Olfactory ensheathing glia injections in Beijing: misleading patients with ALS [0.03%]
北京嗅鞘细胞注射：误导渐冻人患者
Sheena Chew,Alexander G Khandji,Jacqueline Montes et al.
Sheena Chew et al.
Different forms of cell transplantation therapy are being tested in models of ALS. While the approach offers hope to patients with ALS, much still needs to be learned in the laboratory before it is ready for human trials. Nevertheless, clin...
Distinctions between the dementia in amyotrophic lateral sclerosis with frontotemporal dementia and the dementia of Alzheimer's disease [0.03%]
肌萎缩侧索硬化伴额颞痴呆的痴呆与阿尔茨海默病性痴呆的区别
Jennifer Heidler-Gary,Argye E Hillis
Jennifer Heidler-Gary
The clinical entity of Amyotrophic Lateral Sclerosis with Frontotemporal Dementia (ALS-FTD) has only recently been recognized as an important neurodegenerative disease. As in isolated FTD, the behavioral and personality changes in ALS-FTD m...
Survey of ALS-associated factors potentially promoting Ca2+ overload of motor neurons [0.03%]
与ALS相关的可能促进运动神经元钙超载的因素综述
Ilya D Ionov
Ilya D Ionov
The deleterious consequences of Ca(2+) overload are thought to be a probable cause of motoneuronal death in ALS, although the overloading mechanism is currently unclear. In this paper some ALS-linked factors are analysed with regard to thei...
Michael Swash
Michael Swash
Pressure ulcers in ALS patients on admission at a university hospital in Japan [0.03%]
日本一家大学医院ALS患者入院时的压力性溃疡状况
Tomoyo Hayashi,Yugo Narita,Naoko Okugawa et al.
Tomoyo Hayashi et al.
We aimed to review the incidence of pressure ulcers in patients with amyotrophic lateral sclerosis (ALS) on admission at a teaching hospital in Mie, Japan. 592 patients admitted to the neurological ward of Mie University Hospital from 1 Apr...
Negative results of a phase II study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis [0.03%]
高压氧治疗肌萎缩侧索硬化二期研究的阴性结果
Julie Steele,Deepti Zutshi,Walter G Bradley
Julie Steele
Riluzole metabolism and CYP1A1/2 polymorphisms in patients with ALS [0.03%]
ALS患者中CYP1A1/2基因多态性与力如泉代谢的关系研究
Senda Ajroud-Driss,Mohammad Saeed,Humaira Khan et al.
Senda Ajroud-Driss et al.
Riluzole is the only FDA approved drug for the treatment of amyotrophic lateral sclerosis. Riluzole is assumed to be mainly metabolized by the liver cytochrome CYP1A2 and by the extra-hepatic cytochrome CYP1A1. CYP1A2 and CYP1A1 genetic pol...
Paul H Gordon,Bin Cheng,Jacqueline Montes et al.
Paul H Gordon et al.
As the number of potential neuroprotective agents for ALS increases, the need for early phase trials that screen drugs before proceeding to efficacy trials also grows. However, it is not known which outcome measures perform best and also pr...
Alternative trial design in amyotrophic lateral sclerosis saves time and patients [0.03%]
渐冻症的替代试验设计节省时间和患者数量
Geert Jan Groeneveld,Michael Graf,Ingeborg van der Tweel et al.
Geert Jan Groeneveld et al.
A sequential trial design is an alternative for the classical trial design with a fixed sample size, that permits stopping a trial as soon as enough evidence for a treatment effect, or a lack thereof, is obtained. This study aimed to determ...